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ABSTRACT
Objective: Dravet syndrome is a rare neurodevelopmental disorder characterized by seizures and
other neurologic problems. SCN1A mutations account for ;80% of cases. Animal studies have
implicated mutation-related dysregulated cortical inhibitory networks in its pathophysiology. We
investigated such networks in people with the condition.
Methods: Transcranial magnetic stimulation using single and paired pulse paradigms was applied
to people with Dravet syndrome and to 2 control groups to study motor cortex excitability.
Results: Short interval intracortical inhibition (SICI), which measures GABAergic inhibitory
network behavior, was undetectable in Dravet syndrome, but detectable in all controls. Other
paradigms, including those testing excitatory networks, showed no difference between Dravet
and control groups.
Conclusions: There were marked differences in inhibitory networks, detected using SICI
paradigms, while other inhibitory and excitatory paradigms yielded normal results. These human
data showing reduced GABAergic inhibition in vivo in people with Dravet syndrome support
established animal models. Neurology® 2017;88:1659–1665
GLOSSARY
AED 5 antiepileptic drug; ANOVA 5 analysis of variance; APB 5 adductor pollicis brevis; DS 5 Dravet syndrome; HSD 5
honest significant difference; ICF5 intracortical facilitation; LICI5 long interval intracortical inhibition;MEP5motor evoked
potential; rMT 5 resting motor threshold; SICI 5 short interval intracortical inhibition; TMS 5 transcranial magnetic
stimulation.
Dravet syndrome (DS; OMIM #607208) is an epileptic encephalopathy, characterized by
seizures that are often resistant to treatment, and onset is typically with complex febrile seizures,
usually in the first year of life. Substantial developmental delay is a common feature; further
problems, such as gait disorder, feeding or appetite difficulties, behavioral problems, and sleep
disturbance, also occur. Development is normal prior to seizure onset.1,2 Structural brain imag-
ing is usually normal, but various structural abnormalities have been described, including focal
brain atrophy, cortical dysplasia, and hippocampal sclerosis.3 EEG may be normal at seizure
onset, but later typically shows multifocal epileptiform abnormalities and a disturbed back-
ground rhythm.4
Mutations in SCN1A, encoding the a subunit of a voltage-gated sodium channel (Nav1.1),
have been found in .80% of affected individuals; the majority of these mutations arise de
novo,5 and the SCN1A variants include both missense and truncating mutations in addition to
whole gene deletion, suggesting a loss of function mechanism.6
The mechanisms by which SCN1Amutations cause the features of DS have been investigated
using knockout mouse models (Scn1a1/2 and Scn1a2/2). Homozygous Scn1a2/2 mice had
seizures and ataxia, leading to death by day 15, while heterozygous Scn1a1/2 mice showed
spontaneous seizures, but some survived past 15 weeks.7 Whole-cell sodium current recordings
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from mouse neurons suggest that DS-causing
mutations do not affect sodium currents in
excitatory pyramidal cells, a finding that may
be explained by upregulation of other sodium
channels, such as Nav1.3. Recordings from
GABAergic inhibitory interneurons using the
same mouse models show reduced sodium
currents.7,8 This leads to an increased thresh-
old for action potential generation in affected
inhibitory cells.6 It has been suggested that
DS-causing SCN1A mutations reduce the
activity of cortical inhibitory networks, with
the resultant imbalance of neuronal activity
leading to seizures. Apart from seizures,
Scn1a1/2 mice exhibit behavioral problems
such as hyperactivity, cognitive difficulties,
and impaired social interaction. These may
be attributable to reduced GABAergic inhibi-
tion in frontal cortical networks.9 A recent
in vivo study of inhibitory interneurons in
the same mouse model of DS, however, dem-
onstrated normal spontaneous firing patterns,
suggesting that the picture may be more
complex.10
While GABAergic inhibition has been well-
studied in mouse models of DS, little has been
done to understand how inhibitory networks
are affected in humans with DS. An EEG-
fMRI study of 10 people with DS could not
identify a common network underlying epi-
leptiform discharges.11
In the current study, transcranial magnetic
stimulation (TMS) was used to probe cortical
excitability in people with DS. TMS can be
used to stimulate motor cortex noninvasively,
triggering a motor evoked potential (MEP) in
a target muscle. The resting motor threshold
(rMT) measures the ease of activation of
motor cortex via excitatory networks, while
paired pulse paradigms with variable inter-
stimulus intervals test inhibitory and excit-
atory intracortical circuitry.
We hypothesized that GABAergic inhibi-
tion would be reduced in people with DS
compared to control groups. GABAergic
inhibition can be measured using inhibitory
paired pulse paradigms such as short interval
intracortical inhibition (SICI) and long
interval intracortical inhibition (LICI).12
We also hypothesized that rMT and intra-
cortical facilitation (ICF), which are less
influenced by GABAergic inhibition, would
be normal in DS.
METHODS Standard protocol approvals, registrations,
and patient consents. The project was approved by the local
ethical review board (National Research Ethics Service Commit-
tee London: Camden and Islington); TMS parameters were
within current safety guidelines.13 A safety questionnaire was
completed for each participant. Participants gave written
informed consent. In those lacking capacity, a relative was asked
to give assent.
People with DS were identified using an existing clinical
registry. Inclusion criteria for people with DS were as follows:
clinical criteria for diagnosing DS (normal developmental
skills before onset; generalized, or unilateral, or alternating
unilateral hemiclonic, febrile, and afebrile seizures beginning
in the first year of life, with subsequent myoclonic and gener-
alized tonic-clonic seizures and, sometimes, partial seizures;
absence of epileptiform EEG discharges in the initial EEG
studies, if available, with later generalized spike-wave and
polyspike-wave discharges, focal abnormalities, and possible
early photosensitivity; evidence of delayed development from
the second year of life onward1,14) and the presence of an
SCN1A mutation confirmed in a clinically accredited
laboratory.
Six people with DS were recruited. Five had full TMS testing
and 1 only tolerated part of the protocol. Control data were gath-
ered from 10 people with non-DS epilepsy taking antiepileptic
medication and 10 healthy participants.
The technical details of the hardware and software used in this
study have been published, as have the techniques used to identify
the motor hot spot for the adductor pollicis brevis (APB)
muscle.15
The following paradigms were tested: rMT, SICI, ICF, and
LICI. Exact definitions and experimental details of the paradigms
used have been published.15 The following interstimulus intervals
were used: for SICI, 2 and 5 ms; for ICF, 10 and 15 ms; for LICI,
100, 150, 200, and 250 ms.
rMT is a measure of motor cortex excitability, with high rMT
implying low excitability.12 SICI is mediated by GABAAergic
intracortical circuits16 while ICF is mediated by glutamatergic
intracortical circuits, possibly alongside a reduction in GABAergic
inhibition.12 LICI is mediated by GABABergic intracortical
circuits.12
Statistical analysis. rMT for cases and the 2 control groups was
compared using univariate analysis of variance (ANOVA). SICI,
ICF, and LICI results for cases and controls were compared using
multivariate ANOVA for each paradigm. p Values of 0.05 or
lower were interpreted as statistically significant. Post hoc analysis
was performed using Tukey honest significant difference (HSD)
test. All analysis was performed using IBM (Armonk, NY) SPSS
Statistics, version 22.0.
RESULTS Participants. Six adults with typical DS
were recruited (D1–D6); 5 completed all TMS para-
digms, while the 6th subject was unwilling to con-
tinue after initial measurement of rMT. All
participants with DS had a known mutation in
SCN1A (table 1). Control participants included 10
consecutive people with treated non-DS epilepsy
(E1–E10) and 10 healthy controls (H1–H10). Our
healthy control data have been reported.15
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Table 1 shows demographic information, genetic
diagnosis (for those with DS), epilepsy diagnosis
(for epilepsy controls), medication at time of test-
ing, and seizure frequency. There were no signifi-
cant differences in age or sex among the 3 groups
(age: univariate ANOVA p5 0.61; sex: Fisher exact
test p 5 0.68).
Medication and seizure frequency. Those with DS were
taking a mean of 3.2 medications each, while the epi-
lepsy controls were taking a mean of 2.5 medications
each (table 1); there was no significant difference
(unpaired, 2-tailed t test, p 5 0.14). Drugs used in
the 2 groups do not match exactly; 3/6 with DS were
taking stiripentol, which is rarely used outside of DS,
while some epilepsy controls were taking drugs such
as carbamazepine and lamotrigine, which are typically
avoided in DS. Mean reported seizure frequency in
the DS group was 1.3 seizures per day, while epilepsy
controls reported a mean of 1.0 seizure per day; there
was no significant difference (unpaired, 2-tailed t test,
p 5 0.76). Healthy controls were taking no medi-
cation, and reported no seizures.
Resting motor threshold. rMT was measured in 6 peo-
ple with DS. Average rMT was 74.7% of maximum
machine output, SD 10.8%, range 55%–85% (figure
1). This average and range is similar to that seen in
epilepsy controls (75.5%, SD 12.9%, range 59%–
91%; unpaired, 2-tailed t test p 5 0.90), implying
Table 1 Age, sex, mutation (patients with Dravet syndrome only), epilepsy diagnosis (epilepsy controls only), transcranial magnetic
stimulation paradigms tested, medication at time of testing, and seizure frequency for all participants
Participant no. Sex, age, y
SCN1A mutation or
epilepsy diagnosis Testing performed Medication at time of testing, mg/d
Seizure frequency,
seizures/d
D1 F, 34 c.4384T.C rMT, SICI, ICF, LICI CLB 10, PHB 60, TPM 350, VPA 1300 1
D2 M, 20 c.664C.T rMT, SICI, ICF, LICI CLB 10, LEV 250, STP 1750, VPA 500 0.2
D3 F, 41 c.2522C.G rMT, SICI, ICF, LICI CLN 3.5, DZP 10, VPA 2000 0.15
D4 M, 28 c.3706-2A.G rMT, SICI, ICF, LICI CLB 10, TPM 250, VPA 2000 0.8
D5 F, 21 c.429delGT rMT CLB 22.5, STP 2000, VPA 800 2
D6 F, 19 c.787delC rMT, SICI, ICF, LICI STP 2000, VPA 480 2
E1 M, 22 FLE (unknown cause) rMT, SICI, ICF, LICI LTG 200, OXC 1200, TPM 250 7
E2 F, 57 MTLE (HS) rMT, SICI, ICF, LICI LEV 2250, OXC 600, PER 2 0.57
E3 F, 31 MTLE (HS) rMT, SICI, ICF, LICI CLB 10, LCM 200, LEV 3000 0.14
E4 M, 23 TLE (unknown cause) rMT, SICI, ICF, LICI LCM 200, LTG 200 0.03
E5 M, 20 GGE rMT, SICI, ICF, LICI CBZ 1200, LTG 250, 0.14
E6 F, 21 SME (L frontal SH) rMT, SICI, ICF, LICI LEV 3000, OXC 1500 2
E7 M, 35 FLE (unknown cause) rMT, SICI, ICF, LICI LCM 400, LTG 200, LEV 1500 0.29
E8 F, 20 SME (bilateral SH) rMT, SICI, ICF, LICI LEV 1500 2
E9 F, 49 MTLE (HS) rMT, SICI, ICF, LICI CBZ 1400, LEV 2000 0.01
E10 F, 28 GGE rMT, SICI, ICF, LICI CLB 20, OXC 450, PER 8 0.14
H1 F, 34 Healthy Control rMT, SICI, ICF, LICI None NA
H2 F, 36 Healthy Control rMT, SICI, ICF, LICI None NA
H3 M, 35 Healthy Control rMT, SICI, ICF, LICI None NA
H4 F, 30 Healthy Control rMT, SICI, ICF, LICI None NA
H5 M, 32 Healthy Control rMT, SICI, ICF, LICI None NA
H6 M, 42 Healthy Control rMT, SICI, ICF, LICI None NA
H7 M, 27 Healthy Control rMT, SICI, ICF, LICI None NA
H8 F, 30 Healthy Control rMT, SICI, ICF, LICI None NA
H9 M, 29 Healthy Control rMT, SICI, ICF, LICI None NA
H10 M, 23 Healthy Control rMT, SICI, ICF, LICI None NA
Abbreviations: CBZ 5 carbamazepine; CLB 5 clobazam; CLN 5 clonazepam; DZP 5 diazepam; FLE 5 frontal lobe epilepsy; GGE 5 genetic generalized
epilepsy; ICF 5 intracortical facilitation; LCM 5 lacosamide; LEV 5 levetiracetam; LICI 5 long interval intracortical inhibition; LTG 5 lamotrigine; MTLE
(HS) 5 mesial temporal lobe epilepsy (hippocampal sclerosis); OXC 5 oxcarbazepine; PER 5 perampanel; PHB 5 phenobarbital; rMT 5 resting motor
threshold; SH 5 subcortical heterotopia; SICI 5 short interval intracortical inhibition; SME 5 structural-metabolic epilepsy; STP 5 stiripentol; TLE 5
temporal lobe epilepsy; TPM 5 topiramate; VPA 5 valproate.
A breakdown of seizure frequency by seizure type can be found in table e-2.
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similar baseline cortical excitability in the groups.
Meaningful comparison between epilepsy groups
and healthy controls is difficult, since antiepileptic
medication is known to affect rMT. A univariate
ANOVA comparing rMT in all 3 groups showed
significant differences (p 5 0.03); post hoc analysis
confirmed a significant difference only between epi-
lepsy controls and healthy controls (Tukey HSD test;
p 5 0.04).
Short interval intracortical inhibition. SICI paradigms
using ISI of 2 and 5 ms did not cause inhibition in
our DS group. Instead, there was significant facilita-
tion, with mean MEP responses of 2.18 (SD 0.47)
at 2 ms and 1.74 (SD 1.03) at 5 ms normalized to
unconditioned responses. By contrast, all 20 controls,
including those with and without epilepsy, showed
inhibition at an ISI of 2 ms (mean normalized
response 0.44, SD 0.15), and most also showed inhi-
bition at an ISI of 5 ms (mean normalized response
0.86, SD 0.32). Data for SICI across DS and control
groups are shown in figure 2. A multivariate ANOVA
comparing SICI at both ISIs in DS to all controls
showed a significant difference (p , 0.0001). Post
hoc analysis with adjustment for multiple compari-
sons (Tukey HSD test) confirmed a significant dif-
ference between DS and each control group at both
ISIs (2 ms: DS vs epilepsy controls, p , 0.0001; DS
vs healthy controls, p, 0.0001; 5 ms: DS vs epilepsy
controls, p5 0.02; DS vs healthy controls, p5 0.01).
There was no significant difference between non-DS
epilepsy controls and healthy controls at either ISI (2
ms, p 5 0.38; 5 ms, p 5 0.92).
There was no significant difference in ICF or LICI
between any group (figure 2) (multivariate ANOVA,
ICF p 5 0.58, LICI p 5 0.65).
DISCUSSION Our key finding is the lack of GABA-
mediated SICI in people with DS, consistent with our
main hypothesis. There was no inhibition at 2 ms ISI
in any people with DS, while inhibition was detected
in all 20 controls; the difference was significant.
There was also significantly less inhibition in the DS
group at 5 ms ISI.
Instead of the expected normal inhibition of the
MEP at ISIs of 2 and 5 ms, the DS group showed
facilitation. In healthy participants, a subthreshold
conditioning stimulus causes some activity in both
excitatory intracortical and inhibitory intracortical
neurons. In controls, as in the extensive TMS litera-
ture on paired pulse stimulation, the inhibitory effects
were dominant at shorter ISIs (SICI) while the excit-
atory effects were dominant at longer ISIs (intracort-
ical facilitation). In our DS group, the excitatory
effects appeared to be dominant at shorter ISIs. This
may be because the subthreshold conditioning stimu-
lus failed to activate a sufficient number of inhibitory
interneurons to trigger detectable inhibition.
LICI, which is believed to be mediated by the
same GABAergic interneurons, was robustly detect-
able in all groups, with no difference detected
between DS and controls.
Aside from a different ISI, an obvious difference
between SICI and LICI paradigms is that the condi-
tioning pulse in SICI is given at subthreshold inten-
sity, while that in LICI is given at suprathreshold
intensity.
There is a striking parallel between our findings in
people with DS and the data from mouse models of
the condition. Scn1a1/2 mouse inhibitory interneur-
ons showed a reduction in sodium currents, leading
to an increased threshold for action potential genera-
tion in these cells6–8; subthreshold conditioning stim-
uli in our SICI paradigm failed to generate any
detectable inhibition on subsequent MEPs in people
with DS. Suprathreshold stimuli were still able to
generate action potentials in Scn1a1/2 mouse inhibi-
tory interneurons; the suprathreshold conditioning
stimuli in LICI triggered an inhibitory effect on the
MEP similar to that seen in controls.
The presence of normal LICI suggests that inhib-
itory cortical networks are functionally intact in peo-
ple with DS, as indeed they are in the Scn1a1/2
mouse.10 The lack of SICI, however, suggests that
Figure 1 Resting motor threshold (rMT) in all
groups
Mean results for rMT for people with Dravet syndrome (DS),
epilepsy controls, and healthy controls. There was a signifi-
cant difference (indicated by *) between healthy controls
and epilepsy controls (univariate analysis of variance and
post hoc Tukey honest significant difference test; p 5
0.04), but no significant difference between DS and either
control group. Error bars show standard error.
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these inhibitory networks may show reduced
sensitivity.
It is worth noting that a TMS impulse activates ax-
ons directly, while physiologic activation of the same
neurons would occur synaptically. The spreading
depolarization ahead of a synaptically triggered action
potential is much larger than needed to discharge the
membrane and therefore might be relatively insensi-
tive to small changes in membrane threshold. Thus,
the relative insensitivity of inhibitory neurons to sub-
threshold magnetic stimuli in DS may not imply an
equally significant reduction in the physiologic firing
of these neurons. A pattern of reduced sodium chan-
nel function but relatively preserved spontaneous fir-
ing patterns has been shown in animal models.7,10
The fact that our patients with DS were all on
antiepileptic drug (AED) treatment implies that the
therapies used did not fully neutralize the pathologic
effects of the SCN1A mutation. This is consistent
with their clinical presentation; none of our DS group
members was seizure-free.
There are other potential explanations for the lack
of SICI and the presence of LICI in DS. SICI is
believed to be mediated via GABAA receptors on
corticospinal neurons, while LICI is mediated via
GABAB receptors.16 It is possible that expression or
activity of these receptors might be affected unequally
in DS, such that GABAB-mediated inhibition func-
tions normally and GABAA-mediated inhibition does
not. Another possibility is that the longer ISIs in LICI
paradigms are important; for example, the SCN1A
mutation might delay release of GABA from the
inhibitory cortical neurons, thus preventing inhibi-
tion at the shorter ISIs of SICI. A further explanation
would be that the mechanisms controlling SICI are
normal in people with DS, but the inhibition is not
detectable as the SCN1Amutation leads to extra facil-
itation not found in controls. Facilitation can be
found at short ISIs in healthy people, a process
termed short ICF, but this is typically triggered by
a suprathreshold conditioning stimulus.17 ICF uses
a subthreshold stimulus, and was similar in DS and
controls in our study. None of these alternative ex-
planations is supported by the animal data.
rMT was lower in healthy controls compared to
either the DS group or epilepsy controls, although
the comparison between DS and healthy controls
did not reach statistical significance. The difference
is most likely due to effects of the AEDs used by
our DS and epilepsy populations. There was no dif-
ference in rMT between the DS group and epilepsy
controls, who were on a similar number of medica-
tions. Likewise, ICF was similar in DS and controls.
These findings are in keeping with our hypothesis
that DS would not affect rMT or ICF.
AEDs are known to modify TMS results, with dif-
ferent drugs affecting different measures. Our inclu-
sion of a control group with epilepsy is helpful in
this regard, as it demonstrates that SICI is robustly
detectable in people with epilepsy of various types
despite long-term AED treatment, which aids a mean-
ingful comparison between cases and controls. It was
not possible to match exactly the AED exposure of
our patients with DS and epilepsy controls. Sodium
channel-blocking AEDs, including commonly used
AEDs like lamotrigine and carbamazepine, may exac-
erbate DS; they are typically avoided in this popula-
tion. Conversely, stiripentol is in common use in
DS, but is rarely used to treat other types of epilepsy.
Given the impossibility of matching drugs exactly, we
Figure 2 Short interval intracortical inhibition (SICI), intracortical facilitation (ICF), and long interval intracortical inhibition (LICI) in all groups
Mean results for SICI, ICF, and LICI for people with Dravet syndrome (DS), epilepsy controls, and healthy controls. There was a significant difference (indi-
cated by *) between DS and both control groups in SICI only. Error bars show standard error. MEP 5 motor evoked potential.
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instead compared the number of AEDs. Moreover,
although sodium channel blocking AEDs are widely
recognized to increase rMT, they do not affect SICI.18
We consider that disparities between drug types can-
not explain the unusual pattern of SICI in our DS
group.
People with DS commonly have substantial
learning difficulties and may have other behavioral
problems; performing TMS can be challenging in
this population. However, this seems an unlikely
explanation for the robust differences seen in SICI
between our DS and control groups, since other
TMS paired pulse measurements (ICF and LICI)
were no different vs controls. We have previously
reported TMS results in people with alternating
hemiplegia of childhood, a neurodevelopmental
disorder associated with learning and behavioral
difficulties of comparable severity to DS; this group
had normal SICI,15 supporting the specificity of our
results for DS.
Our DS group is smaller than our control groups.
DS is a rare condition, and many people with DS are
not able to undergo TMS testing, due to learning and
behavioral difficulties. People with a more severe phe-
notype were not approached for this study, since it
was believed unlikely that they would tolerate testing;
this is a potential bias (table e-1 at Neurology.org). All
our participants are adults, in whom the electrophys-
iologic profile may differ from that in children.19
Only small numbers of people with DS could be
recruited. The differences in SICI between the DS
and control groups are statistically significant, but
need cautious interpretation and replication.
We used TMS to study motor cortex excitatory
and inhibitory networks in people with DS. There
were clear abnormalities in inhibitory networks, de-
tected using SICI paradigms, while other inhibitory
and excitatory paradigms yielded normal results.
These human data show reduced GABAergic inhibi-
tion in vivo in DS, supporting established animal
models. The specific absence of SICI, in the presence
of normal LICI, suggests that inhibitory networks in
people with DS are functionally intact, but have
a reduced sensitivity to low-intensity stimuli. TMS
measures may provide rapid-readout biomarkers for
cortical excitability and its modulation by treatment
in DS.
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